{"id":1122,"date":"2024-08-05T14:09:15","date_gmt":"2024-08-05T06:09:15","guid":{"rendered":"https:\/\/flcube.com\/?p=1122"},"modified":"2024-10-14T10:24:34","modified_gmt":"2024-10-14T02:24:34","slug":"ge-healthcares-q1-2024-earnings-hit-by-china-adjusts-annual-guidance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=1122","title":{"rendered":"GE Healthcare’s Q1 2024 Earnings Hit by China, Adjusts Annual Guidance"},"content":{"rendered":"\n

GE Healthcare Technologies Inc. (NASDAQ: GEHC<\/a>), a leading player in the medical device and life sciences industry, reported its financial results for the first quarter of 2024, with China’s market dynamics being a significant factor in the company’s decision to adjust its annual guidance downward. The company cited the ongoing anti-corruption campaign and delays in government stimulus programs as key factors contributing to the downgrade.<\/p>\n\n\n\n

Global revenues for GE reached $4.8 billion, marking a modest 1% increase year-on-year in organic terms. Product sales remained stable at $3.2 billion, while services saw a 2% rise to $1.6 billion. Business segment-wise, Imaging was flat at $2.6 billion, Ultrasound dipped 1% to $823 million, Patient Care Services (PCS) grew 1% to $772 million, and Pharmaceutical Diagnostics (PDx) soared 14% year-on-year to $639 million.<\/p>\n\n\n\n

Despite the overall tepid growth, GE revised its full-year revenue outlook, forecasting a more conservative organic revenue growth of 1%-2%, down from the previous expectation of ‘approximately 4%’. This revision was largely attributed to a 18% reported sales decline in China to $583 million in Q1’24, and a 15% decrease over the first half of the year to $1.18 billion. Excluding China, GE’s global growth stood at 4% year-on-year.<\/p>\n\n\n\n

GE’s statement highlighted the timing of a new government stimulus program announced in March 2024 and the lingering effects of the anti-corruption campaign initiated last year as local market negatives. The company anticipates that while the 2024 stimulus program will present long-term opportunities, it has created short-term uncertainty as provinces finalize their plans and customers await details before making purchasing decisions.<\/p>\n\n\n\n

During the earnings call, CEO Peter Arduini expressed a cautious outlook for the China market for the remainder of the year, expecting a continued sales decline and negative growth for the year. The executives refrained from providing a definitive forecast for the China market in 2025, opting for a wait-and-see approach.<\/p>\n\n\n\n

Last year, China accounted for approximately 14% of GE’s overall business, but the company now anticipates this share to contract to around 11%-12% for the current year. However, GE CFO Jay Saccaro expressed long-term optimism regarding China, citing the government’s focus on expanding healthcare access as a positive long-term driver for the company’s business in the country.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

GE Healthcare Technologies Inc. (NASDAQ: GEHC), a leading player in the medical device and life…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,431,1209],"class_list":["post-1122","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-ge-healthcare","tag-nasdaq-gehc"],"yoast_head":"\nGE Healthcare's Q1 2024 Earnings Hit by China, Adjusts Annual Guidance - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GE Healthcare Technologies Inc. (NASDAQ: GEHC), a leading player in the medical device and life sciences industry, reported its financial results for the first quarter of 2024, with China's market dynamics being a significant factor in the company's decision to adjust its annual guidance downward. The company cited the ongoing anti-corruption campaign and delays in government stimulus programs as key factors contributing to the downgrade.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=1122\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GE Healthcare's Q1 2024 Earnings Hit by China, Adjusts Annual Guidance\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=1122\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-05T06:09:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-14T02:24:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1122#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1122\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GE Healthcare’s Q1 2024 Earnings Hit by China, Adjusts Annual Guidance\",\"datePublished\":\"2024-08-05T06:09:15+00:00\",\"dateModified\":\"2024-10-14T02:24:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1122\"},\"wordCount\":366,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"GE Healthcare\",\"NASDAQ: GEHC\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1122#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1122\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=1122\",\"name\":\"GE Healthcare's Q1 2024 Earnings Hit by China, Adjusts Annual Guidance - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-08-05T06:09:15+00:00\",\"dateModified\":\"2024-10-14T02:24:34+00:00\",\"description\":\"GE Healthcare Technologies Inc. (NASDAQ: GEHC), a leading player in the medical device and life sciences industry, reported its financial results for the first quarter of 2024, with China's market dynamics being a significant factor in the company's decision to adjust its annual guidance downward. The company cited the ongoing anti-corruption campaign and delays in government stimulus programs as key factors contributing to the downgrade.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1122#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1122\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1122#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GE Healthcare’s Q1 2024 Earnings Hit by China, Adjusts Annual Guidance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GE Healthcare's Q1 2024 Earnings Hit by China, Adjusts Annual Guidance - Insight, China's Pharmaceutical Industry","description":"GE Healthcare Technologies Inc. (NASDAQ: GEHC), a leading player in the medical device and life sciences industry, reported its financial results for the first quarter of 2024, with China's market dynamics being a significant factor in the company's decision to adjust its annual guidance downward. The company cited the ongoing anti-corruption campaign and delays in government stimulus programs as key factors contributing to the downgrade.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=1122","og_locale":"en_US","og_type":"article","og_title":"GE Healthcare's Q1 2024 Earnings Hit by China, Adjusts Annual Guidance","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=1122","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-08-05T06:09:15+00:00","article_modified_time":"2024-10-14T02:24:34+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=1122#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=1122"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GE Healthcare’s Q1 2024 Earnings Hit by China, Adjusts Annual Guidance","datePublished":"2024-08-05T06:09:15+00:00","dateModified":"2024-10-14T02:24:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=1122"},"wordCount":366,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","GE Healthcare","NASDAQ: GEHC"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=1122#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=1122","url":"https:\/\/flcube.com\/?p=1122","name":"GE Healthcare's Q1 2024 Earnings Hit by China, Adjusts Annual Guidance - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-08-05T06:09:15+00:00","dateModified":"2024-10-14T02:24:34+00:00","description":"GE Healthcare Technologies Inc. (NASDAQ: GEHC), a leading player in the medical device and life sciences industry, reported its financial results for the first quarter of 2024, with China's market dynamics being a significant factor in the company's decision to adjust its annual guidance downward. The company cited the ongoing anti-corruption campaign and delays in government stimulus programs as key factors contributing to the downgrade.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=1122#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=1122"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=1122#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GE Healthcare’s Q1 2024 Earnings Hit by China, Adjusts Annual Guidance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1122"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1122\/revisions"}],"predecessor-version":[{"id":6348,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1122\/revisions\/6348"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}